Skip to content
OpenCapital
Get started

Achieve Life Sciences ACHV EBITDA

Discontinued — last reported Q4 '25

EBITDA at other companies

Sionna Therapeutics, Inc. Common Stock logo
Sionna Therapeutics, Inc. Common StockSION
-$29.45M-51.0%
Pfizer logo
PfizerPFE
——
Philip Morris International logo
Philip Morris InternationalPM
——

Other financials

Income statement

See full
Net income-$10.2M+20.7%
EPS (diluted)-$0.19+48.6%

Balance sheet

See full
Cash & equivalents$28.1M+116%
Total debt$5.6M+332%
Total equity$10.7M+3.9%
Total assets$33.1M+21.0%

Cash flow

See full
Operating cash flow-$6.9M+37.5%
CapEx$750.0—
Free cash flow-$12.4M—

Valuation

See full
Market cap$585.16M+404%
Enterprise value$562.71M+439%

Returns & leverage

See full
Return on equity-496.1%-906pp
Debt / equity0.5×+0.4×
Current ratio2.6×-0.9×

Where this comes from

Calculated from Achieve Life Sciences’s reported figures.

−$13.4Mebit+
$57.0KDepreciation Depletion & Amortization
=-$13.35M

The official record: Achieve Life Sciences’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Achieve Life Sciences's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Achieve Life Sciences's EBITDA?
Achieve Life Sciences (ACHV) reported EBITDA of -$13.35M in Q4 2025.
How has Achieve Life Sciences's EBITDA changed year-over-year?
Achieve Life Sciences's EBITDA decreased by 37.6% year-over-year, from -$9.7M to -$13.35M.
What is the long-term trend for Achieve Life Sciences's EBITDA?
Over 4 years (2021 to 2025), Achieve Life Sciences's EBITDA has grown at a 13.0% compound annual growth rate (CAGR), from -$32.9M to -$53.6M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.